Global X Japan Co. Ltd. Has $3.23 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Global X Japan Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 354.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,181 shares of the biopharmaceutical company’s stock after buying an additional 3,261 shares during the period. Global X Japan Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $3,227,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. CoreCap Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 234.0% during the fourth quarter. CoreCap Advisors LLC now owns 795 shares of the biopharmaceutical company’s stock worth $614,000 after buying an additional 557 shares during the last quarter. Mather Group LLC. raised its holdings in Regeneron Pharmaceuticals by 61.5% in the fourth quarter. Mather Group LLC. now owns 714 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 272 shares during the period. Norden Group LLC lifted its holdings in Regeneron Pharmaceuticals by 31.9% during the fourth quarter. Norden Group LLC now owns 1,459 shares of the biopharmaceutical company’s stock worth $1,126,000 after acquiring an additional 353 shares in the last quarter. Sax Wealth Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $233,000. Finally, Czech National Bank raised its holdings in shares of Regeneron Pharmaceuticals by 2.7% during the fourth quarter. Czech National Bank now owns 26,575 shares of the biopharmaceutical company’s stock worth $20,512,000 after acquiring an additional 702 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on REGN. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Canaccord Genuity Group upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Finally, Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $756.73 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $764.58 and its 200 day simple moving average is $704.71. The firm has a market capitalization of $80.00 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 2.01 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $12.07 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.